Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a clinical-stage Massachusetts-based biotech developing sutantatug envedotin (CRB-701), a Nectin-4 antibody-drug conjugate for oropharyngeal and cervical cancers, and CRB-913, an oral, peripherally restricted CB1 inverse agonist for obesity. In today's session the stock is trading at $2.65, down 11.96% from the prior close of $3.01, and has printed a fresh 52-week low of $2.64. No new press release, filing or clinical disclosure explains the move. Instead, the decline extends a selloff that began after the company's ObesityWeek 2026 poster on CRB-913 and accelerated through a series of analyst price-target revisions following third-quarter results.
The central narrative remains the CANYON-1 Phase 1b readout. Corbus reported statistically significant mean weight loss of 5% at 12 weeks on the 60 mg dose, with no plateau, alongside reductions in waist circumference and BMI and fewer gastrointestinal adverse events than marketed oral GLP-1 therapies. The clinical signal is genuine. The valuation response was not: investors judged 5% at three months as insufficient to differentiate CRB-913 against injectable incretins or against oral programmes from far larger competitors. Because the obesity asset is a major component of the equity story alongside the oncology pipeline, that reassessment has a leveraged effect on the share price.
The Q3 report on November 10 showed a net loss of $37.8 million, or $1.81 per share, well wider than consensus, driven partly by a $15 million CSPC licensing milestone. Corbus closed the quarter with $115.3 million in cash and guided that runway extends into 2028. Revenue was zero, as expected for a clinical-stage company. The wider loss triggered a wave of target cuts — RBC Capital to $33, Mizuho to $23, Wedbush to $27, and a lowered full-year loss estimate from H.C. Wainwright — each paired with a retained Buy or Outperform rating. Lower targets do not change the fundamental case, but they do trim the ceiling that had supported the stock's November rally.
Management took part in a fireside chat at the Jefferies Global Healthcare Conference this morning. Commentary covered TEMPO-1 registrational trial design, the competitive position of sutantatotug envedotin against Padcev in Nectin-4, and encouraging key-opinion-leader feedback from ObesityWeek. No incremental data were disclosed. With the catalysts exhaustively discussed and the next major readout — first-line CRB-701 combination data — not expected before early 2027, the path of least resistance has been lower.
Volume has not been especially heavy relative to the stock's turnover history, with recent sessions running below the roughly 1.1 million-share average, a pattern that magnifies price movement in a name with a market capitalization near $55 million. The move is consistent with the broader retreat in small-cap biotechnology, where financing-dependent, pre-revenue companies are sold first when risk appetite contracts. CRBP has now broken decisively below its prior 52-week floor of $2.81 and sits far beneath its 50-day and 200-day moving averages, a configuration that tends to invite momentum-driven selling.
The score runs from 0, meaning no meaningful news and a price move normal for the stock, to 100, meaning transformative news and an extreme, rare move. CRBP earns 28 out of 100. The verified news is real but moderate and no longer fresh: an obesity dataset that disappointed relative to competitive benchmarks, a wider-than-expected quarterly loss, and several target-price reductions. Judged against a company of this size, none of these is transformative.
The price move was meaningful but not extraordinary. At 11.96%, today's decline is roughly 2.9 times the stock's typical absolute daily move of about 4.2% over the past 60 sessions, and a move of this size or larger has occurred six times in that window. Strong news and an unusual move are both required for a high score; here, modest news and a familiar magnitude combine to produce a low reading.
Attention now shifts to execution on two fronts. On oncology, investors will track enrollment in the TEMPO-1 registrational study of sutantatug envedotin in second-line oropharyngeal cancer and the timing of first-line combination data expected in early 2027. On obesity, the company has signalled plans to engage regulators on a development path for CRB-913 and to evaluate combination use with GLP-1 therapy, with longer-duration weight-loss data the key variable. Fourth-quarter results and the company's year-end cash position will also matter, since a widening loss profile can revive dilution concerns even with runway into 2028. Management appearances at the Evercore Healthcare Conference on December 1 and any subsequent financing activity are near-term items to monitor. Analysts remain overwhelmingly constructive on ratings and targets, but that consensus is precisely what has been under pressure.
Tickeron hosts hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions appear in the curated Trending AI Robots section. The bots differ by strategy, timeframe, performance metrics and the symbols they trade, allowing users to compare approaches side by side. In a tape as volatile as small-cap biotech, seeing which automated strategies are working right now can sharpen a trader's own process. Explore the page and review the current leaders.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Aroon Indicator for CRBP entered a downward trend on November 16, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 288 similar instances where the Aroon Indicator formed such a pattern. In 262 of the 288 cases the stock moved lower. This puts the odds of a downward move at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRBP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The RSI Indicator entered the oversold zone -- be on the watch for CRBP's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for CRBP just turned positive on October 22, 2026. Looking at past instances where CRBP's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.
Following a +13.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRBP advanced for three days, in 226 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CRBP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.581) is normal, around the industry mean (3.592). P/E Ratio (-0.502) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. CRBP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRBP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of drug development services
Industry Biotechnology